ArticleCell reports. Medicine2026
A functional antiplatelet nanomotor for tri-modal ablation of acute arterial thrombus.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Timely and safe thrombolysis is a priority in the clinical management of acute arterial embolism. However, current drug therapies face the challenge of balancing therapeutic benefits with bleeding risks. Nanomotors emerge as a promising nonpharmaceutical modality for embolism recanalization, yet transient physical-force-driven antithrombotic therapy cannot achieve long-acting treatment, resulting in unsatisfactory therapeutic outcomes. Here, we exploit a functional antiplatelet nanomotor, which is precisely assembled from a photothermal photosensitizer (DiR), a photothermal-activatable nitric oxide (NO) donor (BNN6), and an antiplatelet drug (ticagrelor [TGL]). Under laser irradiation, the nanomotor achieves deep thrombus penetration through vigorous propulsion enabled by efficient NO generation, while on-site TGL release acts synergistically with NO to enhance antiplatelet function. As expected, the clot-piercing antiplatelet nanomotor displays striking thrombolytic effects in two artery embolism rat models. This study advances a photothermal/mechanical/antiplatelet tri-modal thrombolytic modality toward clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.